$MAX

MediaAlpha (NYSE:MAX) Reports Upbeat Q2 CY2026, Guides for Strong Sales Next Quarter

MediaAlpha (NYSE:MAX) reported Q2 CY2026 revenue of $316.9 million, up 25.9% year over year, ahead of Wall Street expectations. Midpoint guidance for next-quarter revenue was $342.5 million, slightly above estimates. GAAP EPS was $0.65, well above consensus. The article also cites full-year EPS guidance of $1.11.

Original reporting
Published Jul 29, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MediaAlpha (NYSE:MAX) Reports Upbeat Q2 CY2026, Guides for Strong Sales Next Quarter — source image
Decision brief

The 30-second read

$MAXBullishMed
01

Why it matters

The key tradable inputs are the Q2 revenue and GAAP EPS beat versus expectations and the next-quarter revenue guidance midpoint that is modestly above analysts’ estimates.

02

Market read

A revenue and EPS beat with slightly better-than-expected next-quarter guidance can drive estimate revisions and near-term positioning, even if forward EPS is expected to soften.

03

What to watch

Adjusted operating margin is discussed as improving, but the article does not break out drivers (pricing vs mix vs cost control), leaving uncertainty around sustainability.

Relevance 8/10Novelty 7/10Timing: after-hours/late-day reaction to Q2 CY2026 results and next-quarter revenue guidance

Background

MediaAlpha runs an insurance customer acquisition referral platform, connecting carriers with high-intent consumers across property-casualty, health, and life.

Company-level read

Ticker impact

$MAXBullishMedium confidence
Context

MediaAlpha reported Q2 CY2026 revenue of $316.9M (+25.9% YoY) and guided next-quarter revenue to $342.5M midpoint, above estimates.

Expected impact

Likely near-term positive bias versus pre-report expectations, with follow-through dependent on whether the guidance is sustained.

Evidence & confidence

The article provides concrete Q2 results and a specific next-quarter revenue midpoint above analysts’ estimates, which typically drives short-term repricing.

Market effects

Signals continued demand strength in insurance customer acquisition software/services, potentially supporting the group’s growth narrative.

No specific regional impact described beyond US-listed company results.

No explicit global drivers mentioned; impact appears company-specific.

Counterpoint

Despite the beat, the article notes Wall Street expects full-year EPS to decline 31.6%, which could cap upside if investors focus on earnings durability.

Key entities

  • MediaAlpha

    Insurance customer acquisition platform reporting Q2 CY2026 results and next-quarter revenue guidance.

  • Steve Yi

    CEO quoted saying demand broadened across the marketplace.

Related articles

$MAXHigh

MediaAlpha, Inc. (MAX): Results of Operations and Financial Condition

MediaAlpha, Inc. (MAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 maxq22026-earningsreleasex.htm EX-99.1 Document Exhibit 99.1 MEDIAALPHA ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Second Quarter Revenue Growth of 26%; Record Revenue of $316.9 million Second Quarter Net Income of $41.8 million; Adjusted EBITDA (1) of $29.3 millio

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.